Valence 標誌
熱門
登入
Loading data for DMIIR — first visit, this takes a few seconds.

加入自選清單

Drugs Made In America Acq...

NasdaqGM: DMIIR · 即時價格 · USD
0.09
+0.00 (0.00%)
收盤價： Aug 26, 2026, 3:24 PM

股價、關鍵數字和最新消息，都在這一頁。

Drugs Made In America Acquisition II Corp.（DMIIR）股價、分析與資料

0.00%
買價0.07
市值n/a
營收 (ttm)n/a
淨利（ttm）13.02M
n/a
n/a
n/a
n/a
P/B (ttm)-0.30
P/S (ttm)n/a
財報日期n/a
賣價0.1
成交量2,717
20 日平均成交量
開盤價0.07
前收盤價0.09
當日區間0.09 - 0.09
52 週範圍0.09 - 0.09
分析師n/a
目標價n/a
股利n/a
除息日n/a

關於 DMIIR

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York...

[閱讀更多]
產業
類股
IPO 日期 n/a
員工 n/a
證券交易所 NasdaqGM
股票代號 DMIIR
完整的公司簡介

財務表現

Drugs Made In America Acquisition II 在 undefined 年的營收為 n/a，較前一年的 n/a 增加 undefined%。 淨利為 n/a，較前期增加 undefined%。

財務報表
news image

6 月前 · Motley Fool

NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply Wave

MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and re...

news image

8 月前 · Simply Wall St.

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company

Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...